Allakos, Inc.
(NASDAQ : ALLK)

( )
ALLK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.01%176.960.7%$1383.16m
MRKMerck & Co., Inc. 0.66%92.500.7%$1203.71m
PFEPfizer Inc. 0.55%50.940.9%$1160.82m
LLYEli Lilly & Co. 1.74%323.141.1%$1096.78m
BMYBristol-Myers Squibb Co. -0.53%78.281.0%$1078.11m
ABBVAbbVie, Inc. 0.96%153.951.9%$992.07m
AZNAstraZeneca Plc 1.65%67.021.0%$451.24m
SGENSeagen Inc. 0.33%179.065.7%$322.85m
TPTXTurning Point Therapeutics, Inc. 0.32%75.300.0%$286.13m
GSKGSK Plc 0.97%43.770.2%$281.98m
HZNPHorizon Therapeutics Plc 0.99%82.505.4%$176.10m
NVSNovartis AG 0.70%84.760.2%$166.17m
MRTXMirati Therapeutics, Inc. -1.84%67.241.6%$154.95m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.85%145.640.0%$148.67m
NVONovo Nordisk A/S 1.63%110.060.1%$146.95m

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.